MV-140 is under clinical development by Inmunotek and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect MV-140’s likelihood of approval (LoA) and phase transition for Urinary Tract Infections took place on 28 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their MV-140 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
MV-140 (Uromune) is under development for the treatment of recurrent urinary tract infections (RUTI). MV-140 is a bacterial polyvalent vaccine composed of different proportions of whole heat-inactivated bacteria strains. The vaccine candidate is administered through sublingual route.
Inmunotek opearates as a pharmaceutical company. It develops, produces and markets products for allergy and other immune-based diseases and manufactures veterinary medicine. It also produces raw materials such as biological products, including fungi, bacteria and mites.
Quick View MV-140 LOA Data
|Highest Development Stage|